Loading viewer...
investor_presentation
Format: PDF investor_presentation
J. Michael Bruff Senior Vice President, Investor Relations investors@varian.comApril 24, 2019Second Quarter Fiscal Year 2019
Senior Vice President, Investor Relations
investors@varian.comApril 24, 2019Second Quarter
This presentation is intended exclusively for investors.
It is not intended for use in Sales or Marketing.
Forward -Looking Statements
Except forhistorical information, thispresentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements
concerning industry ormarket outlook, including growth drivers ;thecompany’s future orders, revenues, operating expenses, taxrate, cash flows, earnings growth orother financial
results ;andanystatements using theterms “could,” “believe,” “expect,” “promising,” “outlook,” “should,” “well-positioned,” “will” orsimilar statements areforward -looking statements
thatinvolve risks anduncertainties thatcould cause thecompany’s actual results todiffer materially from those anticipated .Such risks anduncertainties include ourability toachieve
expected synergies from acquisitions ;global economic conditions andchanges totrends forcancer treatment regionally ;currency exchange rates andtaxrates ;theimpact ofthe
TaxCuts andJobs Act;theimpact oftheAffordable Health Care forAmerica Act(including excise taxes onmedical devices) andanyfurther healthcare reforms (including changes
toMedicare andMedicaid), and/or changes inthird-party reimbursement levels ;new andpotential future tariffs oraglobal trade war;demand foranddelays indelivery ofthe
company’s products ;thecompany’s ability todevelop, commercialize and deploy new products ;thecompany’s ability tomeet Food and Drug Administration (FDA) and other
regulatory requirements, regulations orprocedures ;changes inregulatory environments ;thecompany’s assessment ofthegoodwill associated with itsproton solutions business,
risks associated with thecompany providing financing fortheconstruction and start-upoperations ofparticle therapy centers, challenges associated with commercializing the
company’s proton solutions business ;challenges topublic tender awards andthelossofsuch awards orother orders ;theeffect ofadverse publicity ;thecompany’s reliance onsole
orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive products and pricing ;thecompany’s assessment ofthegoodwill
associated with itsproton solutions business ;thepotential loss ofkeydistributors orkeypersonnel ;andtheother risks listed from time totime inthecompany’s filings with the
Securities andExchange Commission, which bythisreference areincorporated herein .Thecompany assumes noobligation toupdate orrevise theforward -looking statements in
this presentation because ofnew information, future events, orotherwise .Reconciliations toGAAP financials can befound inour earnings press release at
www .varian .com/investors andtheappendix tothispresentation .
Varian hasnotfiled itsForm 10-Qforthequarter ended March 29,2019 .Asaresult, allfinancial results described here should beconsidered preliminary, andaresubject tochange
Preview truncated — download the full document for the complete content.
conference
27 Pages